A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
April 23, 2025
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy™ (PRnT™) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet®’s growing role as a transformative, non-invasive solution for veterinary oncology.
April 15, 2025
Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuc
Kennewick, WA - April 15, 2025 Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy™, an FDA-designated Breakthrough Device for the treatment of solid tumors. The latest results highlight both technical progress and growing clinical validation.
This update builds upon the initial results released in February 2025, which confirmed the safety of RadioGel® in the first five patients. As of this report, ten patients with cancerous nodes have now been successfully treated, further establishing a strong safety profile while generating promising early evidence of efficacy.
February 4, 2025
Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans.
(Richland, WA – February 4, 2025) – Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide TherapyTM by satisfying the criteria in the Clinical Study Plan, including confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse reported by any of the initial five patients since the initial treatment date.
December 26, 2024
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Cl
(Richland, WA – December 26, 2024) – Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in veterinary cancer care, and expanding its network of certified clinics across the U.S.
December 23, 2024
Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinic
(Richland, WA– December 23, 2024)– Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies.
October 18, 2024
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide Therapy™ October 18, 2024 08:30 ET | Source: Vivos Inc.
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy.
NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, NJ. provides 24/7/365 emergency, trauma, and critical care and a suite of veterinary specialty services for small animals. They have been approved and licensed to offer IsoPet Precision Radionuclide Therapy as a cancer treatment for small animals.
Dr. Korenko stated “An important objective is to expand the number of clinics that are certified
for IsoPet Therapy. Generally, different clinics specialize in small animal or equine therapy.
Certification is much lower cost than other alternatives that require large capital investments. It
requires veterinarians and oncologists that are enthusiastic about the effectiveness of IsoPet.
Vivos assists them with obtaining or amending their radioactive material license and provides
the certification training that includes our proprietary Injection Guidance Table. We now have
several clinics in the pipeline.”
Michael K. Korenko, Sc.D.
President & CEO Vivos Inc
Email: MKorenko@RadioGel.com
Follow Vivos Inc @VivosIncUSA, RadioGel ® and IsoPet ® on X (Twitter):
September 30, 2024
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc.
We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals.
Dr. Korenko commented, “While we have experience treating cats, dogs, and horses, there is a growing need to address cancer treatment for other pets and zoo animals. We have been attending relevant conferences to raise awareness about using IsoPet Precision Radionuclide Therapy as an innovative cancer treatment for solid cancerous tumors in all animals.”
Michael K. Korenko, Sc.D.
President & CEO Vivos Inc
Press Releases
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
August 07, 2023
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT).
The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire, the Hopkinton Animal Hospital, located in Weare, New Hampshire and the Indian Creek Veterinary Hospital, located in Fort Wayne, Indiana.
Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
January 02, 2018